A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy
Titel:
A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy
Auteur:
Baumann, K.H. du Bois, A. Meier, W. Rau, J. Wimberger, P. Sehouli, J. Kurzeder, C. Hilpert, F. Hasenburg, A. Canzler, U. Hanker, L.C. Hillemanns, P. Richter, B. Wollschlaeger, K. Dewitz, T. Bauerschlag, D. Wagner, U.